JPMorgan analyst David Perry raised the firm’s price target on Exosens (EXOSF) to EUR 60 from EUR 54 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential